Treatment of STAT3-deficient hyper–immunoglobulin E syndrome with monoclonal antibodies targeting allergic inflammation

Abstract

Single transducer and activator of transcription 3 (STAT3) dominant negative (DN) is a primary immunodeficiency (PID) manifested by oto-sinopulmonary and skin bacterial infections; eczematoid dermatitis; mucocutaneous candidiasis; elevated serum immunoglobulin E (IgE); and skeletal, vascular, and connective tissue abnormalities. In recent years, monoclonal antibodies have emerged to manage atopic dermatitis (AD) and eosinophilic disease raising interest in whether STAT3 DN patients could have clinical benefit.